Uncommon Cents Investing LLC Buys 795 Shares of Biogen Inc. (NASDAQ:BIIB)

Uncommon Cents Investing LLC increased its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 21.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,510 shares of the biotechnology company’s stock after buying an additional 795 shares during the quarter. Uncommon Cents Investing LLC’s holdings in Biogen were worth $1,167,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of BIIB. Altshuler Shaham Ltd bought a new position in shares of Biogen during the 4th quarter worth approximately $25,000. OFI Invest Asset Management bought a new stake in Biogen during the third quarter worth $26,000. Gladius Capital Management LP purchased a new position in Biogen in the third quarter worth $28,000. KB Financial Partners LLC boosted its position in Biogen by 105.1% in the third quarter. KB Financial Partners LLC now owns 121 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 62 shares during the last quarter. Finally, CVA Family Office LLC bought a new position in Biogen in the 4th quarter valued at $36,000. 87.93% of the stock is currently owned by institutional investors.

Insider Transactions at Biogen

In other news, Director Eric K. Rowinsky bought 455 shares of Biogen stock in a transaction that occurred on Thursday, February 15th. The shares were acquired at an average price of $222.54 per share, with a total value of $101,255.70. Following the completion of the purchase, the director now directly owns 20,629 shares in the company, valued at $4,590,777.66. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Eric K. Rowinsky acquired 455 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were bought at an average cost of $222.54 per share, with a total value of $101,255.70. Following the acquisition, the director now owns 20,629 shares in the company, valued at approximately $4,590,777.66. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Priya Singhal sold 262 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $221.23, for a total value of $57,962.26. Following the completion of the sale, the insider now owns 4,886 shares of the company’s stock, valued at approximately $1,080,929.78. The disclosure for this sale can be found here. In the last ninety days, insiders sold 789 shares of company stock valued at $182,213. Insiders own 0.60% of the company’s stock.

Wall Street Analyst Weigh In

BIIB has been the subject of several research reports. Truist Financial restated a “buy” rating and set a $340.00 price target on shares of Biogen in a research report on Monday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $311.00 price target on shares of Biogen in a research report on Tuesday, February 20th. Oppenheimer decreased their price objective on Biogen from $295.00 to $290.00 and set an “outperform” rating for the company in a report on Wednesday, February 14th. StockNews.com downgraded shares of Biogen from a “buy” rating to a “hold” rating in a report on Tuesday, February 20th. Finally, Mizuho reduced their target price on shares of Biogen from $355.00 to $277.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. Nine investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat, Biogen currently has a consensus rating of “Moderate Buy” and an average target price of $305.68.

Biogen Stock Performance

Shares of BIIB opened at $215.63 on Friday. Biogen Inc. has a 12-month low of $211.01 and a 12-month high of $319.76. The company has a current ratio of 2.00, a quick ratio of 1.26 and a debt-to-equity ratio of 0.46. The company has a market cap of $31.34 billion, a PE ratio of 27.02, a price-to-earnings-growth ratio of 1.81 and a beta of -0.03. The stock has a 50-day moving average price of $229.71 and a 200-day moving average price of $242.07.

Biogen (NASDAQ:BIIB) last announced its earnings results on Tuesday, February 13th. The biotechnology company reported $2.95 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.18 by ($0.23). Biogen had a net margin of 11.81% and a return on equity of 14.91%. The company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.47 billion. During the same quarter in the previous year, the firm earned $4.05 earnings per share. As a group, equities analysts forecast that Biogen Inc. will post 15.48 earnings per share for the current fiscal year.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.